

Effects of Covid 19 Vaccines

Gender Differences

By Craig Paardekooper (January 10th 2022)

WORLD HEALTH ORGANISATION DATA

Source : <http://www.vigiaccess.org> (enter COMINARTY into search box)

Sex	Count	Percentage
Female	2003837	68
Male	907267	31
Unknown	36895	1

VAERS DATA

Source : <https://vaers.hhs.gov/data/datasets.html>

The VAERS database as of 29th December 2021 for USA (domestic) vaccinations for Pfizer, Moderna and Janssen.

Female 462539 reports

Male 201459 reports

EUDRAVIGILANCE DATA TOTALS

Source : https://www.adrreports.eu/en/search_subst.html#

Moderna

Sex	Cases	%
Female	130,103	69.2%
Male	56,156	29.9%
Not Specified	1,823	1.0%
Total	188,082	100.0%

Pfizer

Sex	Cases	%
Female	478,172	71.5%
Male	180,430	27.0%
Not Specified	9,840	1.5%
Total	668,442	100.0%

Astrazeneca

Sex	Cases	%
Female	303,191	70.8%
Male	115,150	26.9%
Not Specified	9,989	2.3%
Total	428,330	100.0%

Janssen

Sex	Cases	%
Female	24,544	57.0%
Male	17,934	41.7%
Not Specified	544	1.3%
Total	43,022	100.0%

EUDRAVILIGANCE DATA BY SYMPTOMS

Source : https://www.adrreports.eu/en/search_subst.html#

Eudravigilance – Moderna - **(CX-024414)** - (up to 01/01/2022)

Here are the number of cases reported for females and males aged 18-64, by type of disorder.

Disorder	Female	Male
Blood & lymphatic system disorders	6,790	1,573
Cardiac disorders	6,086	4,765
Congenital, familial and genetic disorders	66	41
Ear and labyrinth disorders	3,066	1,358
Endocrine disorders	282	66
Eye disorders	3,607	1,444
Gastro-intestinal disorders	24,238	6,241
Hepatobiliary disorders	262	180
Immune system disorders	2,875	779
Infections and infestations	7,482	3,574
Metabolism and nutrition disorders	1,763	764
Musculoskeletal and connective tissue disorders	34,952	11,814
Cancers, neoplasms, tumours	176	104
Nervous system disorders	45,150	17,460
Renal and urinary disorders	904	572
Respiratory, thoracic and mediastinal disorders	9,324	4,287
Skin and subcutaneous disorders	14,807	4,203
Vascular disorders	5,024	2,295

Eudravigilance – Pfizer – **TOZINAMERAN** - (up to 01/01/2022)

Here are the number of cases reported for females and males aged 18-64, by type of disorder.

Disorder	Female	Male
Blood & lymphatic system disorders	29,155	6,516
Cardiac disorders	23,131	12,604
Congenital, familial and genetic disorders	162	85
Ear and labyrinth disorders	11,809	4,311
Endocrine disorders	1,103	181
Eye disorders	13,202	4,269
Gastro-intestinal disorders	79,906	16,971
Hepatobiliary disorders	643	397
Immune system disorders	10,617	2,342
Infections and infestations	28,774	14,204
Metabolism and nutrition disorders	4,799	1,547
Musculoskeletal and connective tissue disorders	375,397	32,358
Cancers, neoplasms, tumours	496	192
Nervous system disorders	155,126	44,560
Renal and urinary disorders	2,202	1,098
Respiratory, thoracic and mediastinal disorders	35,477	11,969
Skin and subcutaneous disorders	41,639	11,241
Vascular disorders	19,217	6,639

Source : https://www.adrreports.eu/en/search_subst.html#

Eudravigilance – Astrazeneca - (**CHADOX1 NCOV-19**) (up to 01/01/2022)

Here are the number of cases reported for females and males aged 18-64, by type of disorder.

Disorder	Female	Male
Blood & lymphatic system disorders	7,805	2,443
Cardiac disorders	11,008	3,911
Congenital, familial and genetic disorders	105	53
Ear and labyrinth disorders	7,552	2,401
Endocrine disorders	406	106
Eye disorders	11,196	3,644
Gastro-intestinal disorders	69,653	14,753
Hepatobiliary disorders	422	271
Immune system disorders	3,211	783
Infections and infestations	18,909	8,238
Metabolism and nutrition disorders	7,626	1,970
Musculoskeletal and connective tissue disorders	104,942	30,996
Cancers, neoplasms, tumours	298	121
Nervous system disorders	140,458	42,960
Renal and urinary disorders	2,041	925
Respiratory, thoracic and mediastinal disorders	21,551	7,822
Skin and subcutaneous disorders	30,608	8,510
Vascular disorders	13,816	5,212

Eudravigilance – Janssen - (**AD26.COV2.S**) (up to 01/01/2022)

Here are the number of cases reported for females and males aged 18-64, by type of disorder.

Disorder	Female	Male
Blood & lymphatic system disorders	578	355
Cardiac disorders	927	808
Congenital, familial and genetic disorders	16	13
Ear and labyrinth disorders	594	417
Endocrine disorders	57	21
Eye disorders	789	482
Gastro-intestinal disorders	5,874	2,350
Hepatobiliary disorders	21,061	15,044
Immune system disorders	249	172
Infections and infestations	2,133	2,690
Metabolism and nutrition disorders	324	200
Musculoskeletal and connective tissue disorders	9629	4855
Cancers, neoplasms, tumours	28	23
Nervous system disorders	12,066	7,240
Renal and urinary disorders	190	178
Respiratory, thoracic and mediastinal disorders	1,757	1,359
Skin and subcutaneous disorders	1,770	1,166
Vascular disorders	1,489	1,094

PFIZER'S REPORT

A document, provided by Pfizer following a Freedom of Information Request, describes 42,086 adverse events between December 1st 2020 and Feb 28th 2021. See - [Pfizer Leak - see p 16](#) .

In table 1 of that report, you can see the relative number of adverse reactions for females and males

Characteristics		Relevant cases (N=42086)
Gender:	Female	29914
	Male	9182
	No Data	2990
Age range (years): 0.01 -107 years Mean = 50.9 years n = 34952	≤ 17	175 ^a
	18-30	4953
	31-50	13886
	51-64	7884
	65-74	3098
	≥ 75	5214
	Unknown	6876
Case outcome:	Recovered/Recovering	19582
	Recovered with sequelae	520
	Not recovered at the time of report	11361
	Fatal	1223
	Unknown	9400

a. in 46 cases reported age was <16-year-old and in 34 cases <12-year-old.

Females 29,914 adverse reaction cases

Males 9182 adverse reaction cases

If you scroll down to p16 of the report, Pfizer goes into some detail for each of the severe adverse reactions. Remember these reactions all happened in just 90 days from start of deployment of the vaccines, and they are only the ones reported to Pfizer directly.

Adverse Reaction	Female	Male
Cardio-vascular (e.g. Heart attack)	1076	291
Haematological (e.g. Haemorrhage)	676	222
Hepatic (e.g. liver damage)	43	26
Facial Paralysis	295	133
Auto-immune disease	526	156
Musculo-skeletal (e.g. Arthritis, chronic fatigue)	2760	711
Neurological (e.g. seizures, convulsions, multiple sclerosis, tremors)	328	150
Herpes	5969	1860
Renal (e.g. kidney failure)	46	23
Respiratory (e.g. severe acute respiratory distress)	72	58
Thromboembolic (e.g. blood clots)	89	55
Stroke	182	91
Vascular damage	26	6

AESIs^a Category	Post-Marketing Cases Evaluation^b Total Number of Cases (N=42086)
Anaphylactic Reactions <i>Search criteria: Anaphylactic reaction SMQ (Narrow and Broad, with the algorithm applied), selecting relevant cases according to BC criteria</i>	Please refer to the Risk 'Anaphylaxis' included above in Table 4 .
Cardiovascular AESIs <i>Search criteria: PTs Acute myocardial infarction; Arrhythmia; Cardiac failure; Cardiac failure acute; Cardiogenic shock; Coronary artery disease; Myocardial infarction; Postural orthostatic tachycardia syndrome; Stress cardiomyopathy; Tachycardia</i>	<ul style="list-style-type: none"> • Number of cases: 1403 (3.3% of the total PM dataset), of which 241 are medically confirmed and 1162 are non-medically confirmed; • Country of incidence: UK (268), US (233), Mexico (196), Italy (141), France (128), Germany (102), Spain (46), Greece (45), Portugal (37), Sweden (20), Ireland (17), Poland (16), Israel (13), Austria, Romania and Finland (12 each), Netherlands (11), Belgium and Norway (10 each), Czech Republic (9), Hungary and Canada (8 each), Croatia and Denmark (7 each), Iceland (5); the remaining 30 cases were distributed among 13 other countries; • Subjects' gender: female (1076), male (291) and unknown (36); • Subjects' age group (n = 1346): Adult^c (1078), Elderly^d (266) Child^e and Adolescent^f (1 each); • Number of relevant events: 1441, of which 946 serious, 495 non-serious; in the cases reporting relevant serious events; • Reported relevant PTs: Tachycardia (1098), Arrhythmia (102), Myocardial infarction (89), Cardiac failure (80), Acute myocardial infarction (41), Cardiac failure acute (11), Cardiogenic shock and Postural orthostatic tachycardia syndrome (7 each) and Coronary artery disease (6); • Relevant event onset latency (n = 1209): Range from <24 hours to 21 days, median <24 hours;

VARIATION

Once again we see evidence of massive variation – this time, not between batches, but rather between different groups in the population.

The vaccines were granted EUA because they promised to have a consistent reaction for all members of the population – NOT to decimate or seriously afflict one group compared to another.

INTENTION

Here we have a strong warning signal that the vaccines are having a worse effect on women than on men.

- Is this warning signal being acknowledged by govt? No.
- Are they carrying out any investigations? No
- Are they exempting women from vaccination? No

So govt intention is to disregard strong safety signals completely? If their intention is NOT to protect you from harm – AND they are actively promoting the harmful intervention - then we can only conclude that their intention is to harm.

PURPOSE

Once we acknowledge intention to harm, then we can ask WHY. What is the purpose of targeting women in such a comprehensive way?

Harm and injury inhibits reproduction in several ways –

1. Illness is not attractive to others
2. Physical activities become painful or impossible
3. Poisoning of the blood effects pregnancy and child birth

ACTION

What can women do?

1. Do not comply with vaccine mandates
2. Keep your self and your family safe
3. Warn others – raise awareness